1 publication

• Published Subscription Review Article 15 May 2024

  Pharmacological Review On Enzalutamide

  By Sreelatha Gangu, Mahaboobi, Sruthi Katta, Megavath Subhash, Narender Boggula, Rama Rao Tadikonda

  Abstract: A key therapeutic option in the treatment of prostate cancer, especially metastatic castration-resistant prostate cancer (mCRPC), is Enzalutamide, a second-generation anti androgen drug. Enzalutamide, discovered by Charles Sawyer and Michael Jung at the University of California, Los Angeles, was developed and Food and Drug Administration (FDA)-approved in 2012. Its therapeutic significance was further solidified with subsequent extensions in indications to encompass metastatic castration-sensitive prostate cancer and non-metastatic castration-resistant prostate cancer. …

  Published in Trends in Drug Delivery · Vol. 11, Issue 2, 2024 · pp. 7–15 Read article →